Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase domain 20 pseudogene 1 (ADAM20P1) is classified as a pseudogene in the human genome and has no known protein-coding or enzymatic function[1][3]. Pseudogenes are gene-like DNA sequences that have lost their protein-coding ability due to disabling mutations. ADAM20P1 is a member of the ADAM gene family, which typically encodes multidomain proteins involved in processes such as cell adhesion, migration, and proteolysis[2][4]. However, as a pseudogene, ADAM20P1 does not encode a functional protein and does not participate in any known biological processes or serve as a therapeutic target. There are no known drugs or disease associations related to ADAM20P1. The gene is listed in genetic databases (such as NCBI Gene: 317760 and Ensembl: ENSG00000290783) solely for reference, and its main scientific relevance is in genomics or evolutionary studies rather than protein function or drug targeting[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 20 pseudogene 1 (ADAM20P1).